SCHEMBL7836740

SCHEMBL7836740

CCCCOc1cccc2c(C)cccc12

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 7/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 1/20 0.50
CNR1 P21554 3/20 0.49
CNR2 P34972 3/20 0.49
CYP2A6 P11509 1/20 0.48
HTR1D P28221 2/20 0.48
MCHR1 Q99705 1/20 0.44
SLC6A4 P31645 1/20 0.44
HRH1 P35367 1/20 0.44
GAA P10253 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
SLC2A1 P11166 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12405306 0.96 CYP1A2 (0.51) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL30503960 0.90 CYP2C9 (0.59) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL2924471 0.90 CYP2C9 (0.59) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL12405307 0.90 CNR1 (0.49) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL12405308 0.90 CNR1 (0.49) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL12460239 0.89 CNR1 (0.52) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL16519470 0.86 CYP2C9 (0.60) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL8955641 0.84 CNR2 (0.51) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL12968475 0.83 SMN1; SMN2 (0.52) HTR1BCYP1A2CYP2C9CYP2C19CNR1
SCHEMBL19612208 0.83 CYP2C9 (0.49) HTR1BCYP1A2CYP2C9CYP2C19CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0676398-B1 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO CO (JP) 2001-10-24 EP disclosed
US-6117893-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 2000-09-12 US disclosed
EP-1022274-A1 Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use Sankyo Company Limited (JP) 2000-07-26 EP disclosed
US-5977365-A HYPOGLYCEMIC AGENTS SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
US-5962470-A Heterocyclic compounds having anti-diabetic activity and their use SANKYO COMPANY, LIMITED (JP) 1999-10-05 US disclosed
US-5886014-A TREATMENT AND/OR PROPHYLAXIS OF A VARIETY OF DISORDERS, INCLUDING HYPERLIPEMIA, HYPERGLYCEMIA, OBESITY, IMPAIRED GLUCOSE TOLERANCE (IGT), INSULIN RESISTANCE AND DIABETIC COMPLICATIONS SANKYO COMPANY, LIMITED (JP) 1999-03-23 US disclosed
US-5834501-A TREATING DIABETES OR HYPERLIPEMIA SANKYO COMPANY, LIMITED (JP) 1998-11-10 US disclosed
US-5739345-A HYPOGLYCEMIC AND ANTIDIABETIC AGENTS SANKYO COMPANY, LIMITED (JP) 1998-04-14 US disclosed
US-5624935-A ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS SANKYO COMPANY, LIMITED 1997-04-29 US disclosed
EP-0745600-A1 Benzimidazole derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-12-04 EP disclosed
EP-0676398-A2 Heterocyclic compounds having anti-diabetic activity, their preparation and their use SANKYO COMPANY LIMITED (JP) 1995-10-11 EP disclosed